Baumgartner R W, Georgiadis D
Neurologische Klinik, Universitätsspital Zürich, Schweiz.
Praxis (Bern 1994). 2003 Jan 29;92(5):168-78. doi: 10.1024/0369-8394.92.5.168.
This paper reviews secondary prevention of stroke by the therapy of vascular risk factors, anticoagulation, surgical and endovascular procedures. Two recently published studies, the PROtection aGainst REcurrent Stroke Study (PROGRESS) and the Heart Protection Study (HPS) demonstrated for the first time the efficacy of antihypertensive and lipid lowering by statins in stroke secondary prevention. PROGRESS has shown that the combination of perindoprile and indapamide reduced the occurrence of ischemic and hemorrhagic strokes in hyper- and normotensive patients by 40%, whereas HPS demonstrated a 20% reduction of ischemic strokes in cases with normal or elevated serum cholesterol. Symptomatic carotid stenoses with a distal degree of > or = 70% should undergo endarterectomy; in the presence of a distal degree of stenosis of 50-69% an individual treatment decision is performed; carotid surgery is not indicated in < 50% stenoses. Patients with a cardiac source of embolism (except those with cardiac myxoma or bacterial endocarditis) should be anticoagulated with a target INR of 2.5 (range 2-3). Patients who have no indication for vascular surgery or anticoagulation will be treated with platelet inhibitors. Aspirin 100 mg/d or the combination aspirin-dipyridamole are the treatment of choice. If cerebral ischemia reoccurs with aspirin or in case of aspirin intolerance clopidogrel will be administered. Patients with cerebral ischemia occurring while they are treated with clopidogrel may receive an oral anticoagulation with a target INR of 2.0 (range 1.5-2.5).
本文综述了通过血管危险因素治疗、抗凝、外科手术及血管内介入手术对卒中进行二级预防的情况。最近发表的两项研究,即预防复发性卒中研究(PROGRESS)和心脏保护研究(HPS),首次证明了使用他汀类药物进行降压和降脂治疗在卒中二级预防中的有效性。PROGRESS研究表明,培哚普利和吲达帕胺联合使用可使高血压和血压正常患者的缺血性和出血性卒中发生率降低40%,而HPS研究表明,血清胆固醇正常或升高的患者缺血性卒中发生率降低20%。远端狭窄程度≥70%的有症状颈动脉狭窄患者应接受颈动脉内膜切除术;远端狭窄程度为50% - 69%时,需进行个体化治疗决策;狭窄程度<50%时则不建议进行颈动脉手术。有心脏栓塞源的患者(患有心脏黏液瘤或细菌性心内膜炎的患者除外)应进行抗凝治疗,目标国际标准化比值(INR)为2.5(范围2 - 3)。无血管手术或抗凝指征的患者将接受血小板抑制剂治疗。首选治疗药物为阿司匹林100mg/天或阿司匹林与双嘧达莫联合使用。如果使用阿司匹林时再次发生脑缺血或患者对阿司匹林不耐受,则给予氯吡格雷治疗。接受氯吡格雷治疗时发生脑缺血的患者可接受口服抗凝治疗,目标INR为2.0(范围1.5 - 2.5)。